Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07041099 · ClinicalTrials.gov registry record · Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A Phase 1 study of Sjogren's Syndrome and Sjogren Disease, sponsored by Cullinan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT07041099 is a Phase 1 study of Sjogren's Syndrome and Sjogren Disease that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 36 participants, below the 286-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 5 states.
The verdict
NCT07041099, a Phase 1 study of Sjogren's Syndrome and Sjogren Disease, is actively recruiting participants, sponsored by Cullinan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
Conditions Studied
Interventions
- DRUG CLN-978
Study Locations (11)
Other
- Cullinan Investigative Site - Brest
- Cullinan Investigative Site - Le Kremlin-Bicêtre
- Cullinan Investigative Site - Strasbourg
- Cullinan Investigative Site - Erlangen
- Cullinan Investigative Site - Hanover
- Cullinan Investigative Site - Roma
Texas
- Cullinan Investigative Site - Plano
- Cullinan Investigative Site - Webster
Florida
- Cullinan Investigative Site - Orlando
Tennessee
- Cullinan Investigative Site - Memphis
Utah
- Cullinan Investigative Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2029-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07041099
The ClinicalTrials.gov registry entry for NCT07041099 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (87% lower). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sjogren's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which CLN-978 is the first listed.
NCT07041099 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT07041099 about?
NCT07041099 is a clinical study titled "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease". A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
What is the current status of trial NCT07041099?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-10-01. Estimated completion is 2029-03-15.
What conditions does trial NCT07041099 study?
This clinical trial studies the following conditions: Sjogren's Syndrome, Sjogren Disease, Sjögren.
What interventions are being tested in trial NCT07041099?
The interventions under investigation include: CLN-978 (DRUG).
Who is sponsoring clinical trial NCT07041099?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07041099 being conducted?
This trial has 11 study locations across Florida, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
COMPLETED · Phase 1
-
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
COMPLETED · Phase 1
-
Omalizumab for Lupus
COMPLETED · Phase 1
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.